Exhibit 11

In the Matter Of:

NEW ENGLAND COMPOUNDING PHARMACY INC. PRODUCTS LIABILITY

DEPOSITION OF

LLOYD R. SABERSKI, M.D.

January 12, 2017



1201West Peachtree Street Suite 2300 Atlanta, GA 30309 404.847.0999

NEW ENGLAND COMPOUNDING PHARMACY INC. PRODUCTS LIABILITY LLOYD R. SABERSKI, M.D. on 01/12/2017

DEPOSITION OF

1	IN THE UNITED STATES DISTRICT COURT			
2	DISTRICT OF MASSACHUSETTS			
3				
4	IN RE NEW ENGLAND COMPOUNDING MDL NO. 02419			
5	PHARMACY, INC. PRODUCTS LIABILITY DOCKET NO.			
6	LITIGATION 1:13-MD-2419-RWZ			
7	THIS DOCUMENT RELATES TO:			
8	All Actions			
9				
10	Deposition of LLOYD R. SABERSKI, M.D.			
11	Baltimore, Maryland			
12	Thursday, January 12, 2017			
13	10:00 a.m.			
14				
15				
16				
17				
18				
19				
20	Reported by: Angela McKinney, Court Reporter			
21				
22				



NEW ENGLAND COMPOUNDING PHARMACY INC. PRODUCTS LIABILITY LLOYD R. SABERSKI, M.D. on 01/12/2017

DEPOSITION OF Pages 162..165

	TETT. ORBEITOTT, INIES. OTT OTT FEED TO		<u> </u>
1	Page 162 England Compounding Pharmacy. Manager of record is	1	Page 164 didn't see any problems listed.
2	Barry Cadden. At the bottom above daily pharmacy	2	BY MR, KIRBY:
3	volume, it says compounding sterile and	3	Q Okay. You would expect that if the
4	A Nonsterile.	4	Massachusetts Board of Pharmacy was inspecting a
5	Q nonsterile. So they go through I guess	5	facility, that they were doing so in an effort to make
6	and do their audit of their inspection. Would you flip	6	sure that they were equipped to properly do their job,
7	to page 3 of 7. It is also Bates stamped BORP9939.	7	right?
8	It's security, 24/7 security monitoring,	8	A Yes.
9	licensure/registration, status of pharmacy staff. They	9	Q I think you talked earlier about
10	are all "yes." Standards for prescription labeling and	10	prescriptions and you said that a patient-specific
11	format, they are all "yes." Do you see that?	11	prescription was required to order drugs from NECC if
12	A Yes.	12	there was a need?
13	Q It says "labels compliant with nature of	13	A Yes.
14	practice." Do you see that?	14	Q We'll assume that part. Can you provide any
15	A Yes.	15	evidence whatsoever that any health care providers
16	Q So the Massachusetts Board of Pharmacy	16	actually ordered from NECC after submitting
17	didn't have a problem with their labeling, right?	17	patient-specific prescriptions?
18	MR. COREN: Objection as to form,	18	MR. COREN: Objection as to the form.
19	BY MR. KIRBY:	19	A I don't understand the question.
20	Q Prescription labeling format.	20	BY MR. KIRBY:
21	A I don't know what that means.	21	Q So all I want to know is do you have any
22	Q This is what the Massachusetts board found.	22	evidence to show me that any customers of NECC actually
			Page 16
1	Page 163 A But I don't know how to interpret what this	1	
2	means or what the standards are.	2	patient-specific prescriptions?
3	Q Okay.	3	A Well, I have evidence.
4	A Whatever it says, whatever their conclusions	4	Q Can you provide strike that.
5	were I don't challenge.	5	MR. KIRBY: Let's go off the record.
6	Q Page five, continuous quality improvement	6	(Off the record)
7	was all checked "yes." Sanitation was all checked	7	BY MR. KIRBY:
8	"yes." At then at the bottom on page 7 of 7 it says	8	Q In reading Dr. Bhambhani's deposition and
9	they service multiple states and licensed in 48 states	9	your other review of records in this case, you
10	and two that don't require licensing. Do you see that?	10	understand that Dr. Bhambhani and others followed
11	So it looks like they were licensed in every state	11	NECC's instructions and used a, quote, prescription
12	across the country, right?	12	order form when ordering from NECC, right?
13	A I think there are 50 states, correct?	13	A Yes.
14	Q I'm sorry. You are right. They sell in 50	14	Q And the Massachusetts Board of Pharmacy
15	states. They are licensed in 48 and then the other two	15	and/or the FDA were aware of that form and the way in
16	don't require licenses. I meant to say that they	16	which NECC was sending out drugs, correct?
17	practice in 50 states.	17	MR. COREN: I want to note my objection to
18	A Okay.	18	the form.
19	Q So it looks like the Massachusetts Board of	19	A I can't speak to what the FDA knew or didn'
20	Pharmacy didn't have a problem with NECC, right?	20	know, but that would be inappropriate.
21	MR. COREN: Objection as to the form.	21	BY MR. KIRBY:
22	A I don't know how to interpret that form, I	22	Q You said that if the FDA and/or the
1 ~~		1	- ·



NEW ENGLAND COMPOUNDING PHARMACY INC. PRODUCTS LIABILITY LLOYD R. SABERSKI, M.D. on 01/12/2017

DEPOSITION OF Pages 166..169

	Page 166		Page 168
1	Massachusetts Board of Pharmacy had information that	1	BY MR. KIRBY:
2	that's the way that NECC was conducting business that	2	Q Even if she had done it that way, she still
3	that would be inappropriate, correct?	3	would have gotten back contaminated drugs?
4	A Yes.	4	A I think that's basically correct, but there
5	Q But they didn't stop NECC from selling	5	is a small caveat here, and we kind of pounded this to
6	drugs, did they, until the outbreak?	6	the ground earlier, that she was getting multidose
7	MR. COREN: Objection as to the form.	7	vials without a preservative and by getting shipped a
8	A Well, they did at the outbreak.	8	multidose vial without preservative, by accessing it
9	BY MR. KIRBY:	9	multiple times, if that vial happened to be bad, she's
10	Q Prior to the outbreak, they didn't stop	10	potentially vectoring bad stuff to multiple people.
11	them?	11	Q But specific to the prescription issue, that
12	A In 2002 I think they were trying to.	12	in and of itself didn't have an effect? Didn't change
13	Q They didn't prevent NECC from continuing to	13	the outcome?
14	sell their drugs all across the country, right? Or at	14	MR. COREN; Objection as to the form.
15	least in Maryland? We'll go with that.	15	A Probably not. I could probably draw some
16	A I don't know whose jurisdiction it was for	16	we'll just say that.
17	that kind of step, but that's not really my area of	17	BY MR, KIRBY;
18	expertise.	18	Q Would you agree that Dr. Bhambhani was
19		19	essentially ordering NECC's MPA and other drugs I guess
	Q Probably should have been one or the other at least, right?	20	for office use?
20		21	A Well, I don't know what her facility is.
21	A Right.	22	Isn't it a surgery center?
22	Q Maybe even both?	22	ish tha surgery tenter.
Ι,	Page 167 MR, COREN: Objection as to form.	1	Page 169 Q An ambulatory surgery center.
1	Č	2	A I think you have to be careful about how you
2	BY MR, KIRBY:	3	use your words. A surgery center is different than an
3	Q And you are not aware, and if you are, just		office. She may very well have been using them in
4	provide me the information, that anyone at the Maryland	4	
5	Board of Physicians, the Board of Pharmacy, the	5	both, but I'm aware of the surgery center stuff.
6	Massachusetts Board of Pharmacy, the FDA, the CDC, the	6	Q Pardon my incorrect grammar, but when I said
7	DEA, et cetera, ever told Dr. Bhambhani or anyone that	7	office, I was suggesting the surgery center.
8	they were ordering the drugs wrong and that they	8	A Okay,
9	couldn't do it that way? You don't have any evidence	9	Q And if she had ordered from an FDA
10			
ł	of that, do you?	10	manufacturer, she wouldn't have needed a prescription,
11	of that, do you? $ \hbox{A} \text{Two questions.} \hbox{I have no evidence and I'm} $	10 11	right?
11 12		1	·
1	A Two questions. I have no evidence and I'm	11	right? A Right, FDA manufacturers, you are allowed to order a stock.
12	$\mbox{\bf A}$. Two questions. I have no evidence and I'm not aware of anybody telling her that.	11 12	right? A Right, FDA manufacturers, you are allowed
12 13	A Two questions. I have no evidence and I'm not aware of anybody telling her that. Q Can we at least agree so I understand	11 12 13	right? A Right, FDA manufacturers, you are allowed to order a stock.
12 13 14	A Two questions. I have no evidence and I'm not aware of anybody telling her that. Q Can we at least agree so I understand your position, then, that she was violating standards	11 12 13 14	right? A Right, FDA manufacturers, you are allowed to order a stock. Q That's essentially what Dr. Ehambhani was
12 13 14 15	A Two questions. I have no evidence and I'm not aware of anybody telling her that. Q Can we at least agree so I understand your position, then, that she was violating standards because she should have used patient-specific	11 12 13 14 15	right? A Right. FDA manufacturers, you are allowed to order a stock. Q That's essentially what Dr. Bhambhani was doing here, correct?
12 13 14 15 16	A Two questions. I have no evidence and I'm not aware of anybody telling her that. Q Can we at least agree so I understand your position, then, that she was violating standards because she should have used patient-specific prescriptions or whatever. Okay. Let's assume that	11 12 13 14 15 16	right? A Right. FDA manufacturers, you are allowed to order a stock. Q That's essentially what Dr. Ehambhani was doing here, correct? A Right, which was against the law.
12 13 14 15 16 17	A Two questions. I have no evidence and I'm not aware of anybody telling her that. Q Can we at least agree so I understand your position, then, that she was violating standards because she should have used patient-specific prescriptions or whatever. Okay. Let's assume that she had a need to use a compounding pharmacy, a	11 12 13 14 15 16	right? A Right. FDA manufacturers, you are allowed to order a stock. Q That's essentially what Dr. Ehambhani was doing here, correct? A Right, which was against the law. Q I may have asked this before and I can't
12 13 14 15 16 17 18	A Two questions. I have no evidence and I'm not aware of anybody telling her that. Q Can we at least agree so I understand your position, then, that she was violating standards because she should have used patient-specific prescriptions or whatever. Okay. Let's assume that she had a need to use a compounding pharmacy, a justifiable need to use a compounding pharmacy, and	11 12 13 14 15 16 17 18	right? A Right, FDA manufacturers, you are allowed to order a stock. Q That's essentially what Dr. Bhambhani was doing here, correct? A Right, which was against the law. Q I may have asked this before and I can't remember so I'll ask it this time. We can agree the
12 13 14 15 16 17 18 19	A Two questions. I have no evidence and I'm not aware of anybody telling her that. Q Can we at least agree so I understand your position, then, that she was violating standards because she should have used patient-specific prescriptions or whatever. Okay. Let's assume that she had a need to use a compounding pharmacy, a justifiable need to use a compounding pharmacy, and that she was submitting individual patient	11 12 13 14 15 16 17 18 19	right? A Right. FDA manufacturers, you are allowed to order a stock. Q That's essentially what Dr. Bhambhani was doing here, correct? A Right, which was against the law. Q I may have asked this before and I can't remember so I'll ask it this time. We can agree the drugs, the MPA that she's ordering is never going in
12 13 14 15 16 17 18 19 20	A Two questions. I have no evidence and I'm not aware of anybody telling her that. Q Can we at least agree so I understand your position, then, that she was violating standards because she should have used patient-specific prescriptions or whatever. Okay. Let's assume that she had a need to use a compounding pharmacy, a justifiable need to use a compounding pharmacy, and that she was submitting individual patient prescriptions. We can at least agree that that had no	11 12 13 14 15 16 17 18 19 20	right? A Right, FDA manufacturers, you are allowed to order a stock. Q That's essentially what Dr. Bhambhani was doing here, correct? A Right, which was against the law. Q I may have asked this before and I can't remember so I'll ask it this time. We can agree the drugs, the MPA that she's ordering is never going in the patient's hands, right? It's always going to be just used by and administered by a skilled professional

